Abstract 4971: Dominant Negative PD 1 Armored CAR T Cells Induce Remission in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients

Tong Chen,Yan Yuan,Liansheng Huang,Chengfei Pu,Tianling Ding,Xibin Xiao,Zhiyuan Cao,Ting Wu,Luying Ding,He Sun,Zhao Wu,Lei Xiao,Xiaohong Zhang

DOI: https://doi.org/10.1158/1538-7445.sabcs18-4971

2019-01-01

Immunology

Abstract:Anti-CD19 chimeric antigen receptor (CAR19) autologous T cell treatment has been demonstrated as effective therapy to relapse/refractory B cell leukemia and lymphoma. However, CAR T shows limited efficacy in treatment of solid tumor or challenging with immunosuppressive characters, such as PD-L1+/hi lymphomas. PD-1/PD-L1 blockade have been shown as potentially effective anti-tumor therapies. We generated a lenti-vector incorporating an anti-CD19 secondary CAR molecule sequence with 4-1BB co-stimulatory domain and a dominant negative PD-1 sequence (Figure A). Compared with conventional CART cells, these ”armored” CART cells show enhanced capability of tumor killing after multiple-round challenging by PD-L1+CD19+ positive tumors, with a ”emory-like” phenotype(Figure B), suggesting dominant negative PD-1 molecule may protect CART cells from inhibition in tumor micro-environment. Here we report 2 cases of refractory diffuse large B cell lymphomas (DLBCLs) successfully treated with this novel dominant negative PD-1 armored humanized anti-CD19 CART cells. These two patients all failed to achieve response after multiple rounds of chemotherapy and radiotherapy, and infused with autologous CAR T cells at 5.23×10^6/kg and 1.97×10^6/kg during disease progress. Both patients showed significantly tumor mass decrease and SUV max decline in PET/CT results with ongoing response. (From 34.48 to 3.89 at day 27, from 25.02 to 2.38 at day 31, respectively.) (Figure C). Conclusion: These 2 cases revealed the significant anti-bulky lymphoma response of new type of CAR19 T cells with limited and tolerated cytokine release syndrome and central nervous system toxicity. This novel structure of dnPD1-hCAR19 may augment CART cells persistence in the patient after activation triggered by the lymphoma cells, suggesting that dnPD-1 molecule may enhance efficacy of CAR T cells in treatment of solid tumor. We are continuing to recruit more patients in clinical research. Citation Format: Tong Chen. Dominant negative PD 1 armored CAR T cells induce remission in refractory diffuse large B-cell lymphoma (DLBCL) patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4971.